연구동향 분석

Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer

오도연 Toshihiko Doi Kuniaki Shirao 이근욱 박숙련 Ying Chen Liqiang Yang Olga Valota 방영주 2015년

논문상세정보
인용/피인용
' Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • axitinib
  • capecitabine
  • cisplatin
  • clinical trial
  • pharmacokinetics
  • phase i
  • stomach neoplasms
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,795 0

0.0%

' Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer' 의 참고문헌

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial
    Bang YJ Lancet 376 : 687 ~ 697 [2010]
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang YJ Lancet 376 687-697 [2010]
  • Sunitinib (SU) with cisplatin (P) and capecitabine (X) or oxaliplatin (O) and X (XELOX) in advanced gastric cancer (GC): a phase I, dose-finding study
    Park SR the 35th Annual Congress of the European Society for Medical Oncology (ESMO) [2010]
  • Sunitinib (SU) with cisplatin (P) and capecitabine (X) or oxaliplatin (O) and X (XELOX) in advanced gastric cancer (GC): a phase I, dose-finding study
    Park SR - [2010]
  • Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
    Go RS J Clin Oncol 17 : 409 ~ 422 [1999]
  • Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
    Go RS J Clin Oncol 17 409-422 [1999]
  • Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer
    Rugo HS J Clin Oncol 29 : 2459 ~ 2465 [2011]
  • Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer
    Rugo HS J Clin Oncol 29 2459-2465 [2011]
  • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial
    Fuchs CS Lancet 383 : 31 ~ 39 [2014]
  • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial
    Fuchs CS Lancet 383 31-39 [2014]
  • Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
    Maeda K Cancer 77 : 858 ~ 863 [1996]
  • Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
    Maeda K Cancer 77 858-863 [1996]
  • Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma
    Shi H World J Gastroenterol 9 : 1421 ~ 1426 [2003]
  • Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma
    Shi H World J Gastroenterol 9 1421-1426 [2003]
  • Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Bang YJ Invest New Drugs 29 : 1449 ~ 1458 [2011]
  • Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Bang YJ Invest New Drugs 29 1449-1458 [2011]
  • Phase I trials of molecularly targeted agents:should we pay more attention to late toxicities?
    Postel-Vinay S J Clin Oncol 29 : 1728 ~ 1735 [2011]
  • Phase I trials of molecularly targeted agents:should we pay more attention to late toxicities?
    Postel-Vinay S J Clin Oncol 29 1728-1735 [2011]
  • Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Kim C Invest New Drugs 30 : 306 ~ 315 [2012]
  • Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Kim C Invest New Drugs 30 306-315 [2012]
  • Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin
    Vermorken JB Cancer Treat Rep 68 : 505 ~ 513 [1984]
  • Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin
    Vermorken JB Cancer Treat Rep 68 505-513 [1984]
  • Nonclinical antiangiogenesis and antitumor activities of axitinib(AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
    Hu-Lowe DD Clin Cancer Res 14 : 7272 ~ 7283 [2008]
  • Nonclinical antiangiogenesis and antitumor activities of axitinib(AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
    Hu-Lowe DD Clin Cancer Res 14 7272-7283 [2008]
  • NCCN clinical practice guidelines in oncology (NCCN Guidelines™) v2.2013gastric cancer
    National Comprehensive Cancer Network National Comprehensive Cancer Network
  • Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma
    Fruehauf J Clin Cancer Res 17 : 7462 ~ 7469 [2011]
  • Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma
    Fruehauf J Clin Cancer Res 17 7462-7469 [2011]
  • GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10
    Ferlay J International Agency for Research on Cancer
  • Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer : an open-label randomised phase II study
    Spano JP Lancet 371 : 2101 ~ 2108 [2008]
  • Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer : an open-label randomised phase II study
    Spano JP Lancet 371 2101-2108 [2008]
  • Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer : results from a phase II study
    Schiller JH J Clin Oncol 27 : 3836 ~ 3841 [2009]
  • Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer : results from a phase II study
    Schiller JH J Clin Oncol 27 3836-3841 [2009]
  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma(AXIS) : a randomised phase 3 trial
    Rini BI Lancet 378 : 1931 ~ 1939 [2011]
  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Rini BI Lancet 378 1931-1939 [2011]
  • Clinical pharmacology of axitinib
    Chen Y Clin Pharmacokinet 52 : 713 ~ 725 [2013]
  • Clinical pharmacology of axitinib
    Chen Y Clin Pharmacokinet 52 713-725 [2013]
  • Capecitabine : a review
    Walko CM Clin Ther 27 : 23 ~ 44 [2005]
  • Capecitabine : a review
    Walko CM Clin Ther 27 23-44 [2005]
  • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
    Ohtsu A J Clin Oncol 29 3968-3976 [2011]
  • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a randomized, double-blind, placebo-controlled phase III study
    Ohtsu A J Clin Oncol 29 : 3968 ~ 3976 [2011]
  • Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer : results from a phase II study
    Cohen EE J Clin Oncol 26 : 4708 ~ 4713 [2008]
  • Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer : results from a phase II study
    Cohen EE J Clin Oncol 26 4708-4713 [2008]
  • Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer : a randomized phase 2 study
    Infante JR Cancer 119 : 2555 ~ 2563 [2013]
  • Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer : a randomized phase 2 study
    Infante JR Cancer 119 2555-2563 [2013]
  • An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
    Moehler M Eur J Cancer 47 : 1511 ~ 1520 [2011]
  • An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
    Moehler M Eur J Cancer 47 1511-1520 [2011]